Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 09 Jul 2019 According to ClinicalTrials.gov record, Darcy V Spicer, MD University of Southern California is the principal investigator of the study.
- 04 Jun 2019 Results (n=10) published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology.
- 31 Jul 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center: 1B12-10).